Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.78 USD | -1.35% | +6.62% | +66.26% |
May. 02 | Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target | MT |
Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
Financials (USD)
Sales 2024 * | 6.82M | Sales 2025 * | 5.17M | Capitalization | 1.46B |
---|---|---|---|---|---|
Net income 2024 * | -172M | Net income 2025 * | -182M | EV / Sales 2024 * | 121 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 218 x |
P/E ratio 2024 * |
-9.86
x | P/E ratio 2025 * |
-11
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.42% |
Latest transcript on Spyre Therapeutics, Inc.
1 day | -1.35% | ||
1 week | +10.19% | ||
Current month | +8.33% | ||
1 month | +4.28% | ||
3 months | +39.01% | ||
6 months | +210.86% | ||
Current year | +66.26% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Russell Cox
CHM | Chairman | 60 | 15-05-31 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 35.78 | -1.35% | 196,820 |
24-05-02 | 36.27 | +7.09% | 389,590 |
24-05-01 | 33.87 | +2.54% | 670,906 |
24-04-30 | 33.03 | -5.33% | 489,376 |
24-04-29 | 34.89 | +3.96% | 361,275 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.26% | 1.46B | |
-1.43% | 103B | |
+8.96% | 101B | |
+4.40% | 23.07B | |
-12.15% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.04% | 16.94B | |
+6.79% | 14.07B | |
+38.61% | 12.35B |
- Stock Market
- Equities
- SYRE Stock